Ignite Creation Date:
2024-05-06 @ 3:24 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04628325
Status:
COMPLETED
Last Update Posted:
2020-11-13
First Post:
2020-11-02
Brief Title:
Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction HFrEF
Sponsor:
University of Palermo
Organization:
University of Palermo
Study Overview
Official Title:
Effects of Treatment With Intravenous Furosemide Plus Small Hypertonic Saline Solutions HSS on Atrial Stretching Fibrosis and Inflammatory Markers in Subjects With Heart Failure With Reduced Ejection Fraction
Status:
COMPLETED
Status Verified Date:
2020-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators sought to evaluate the effectiveness of treatment with furosemide HSS in terms of reduction of serum levels of some chosen markers of heart failure and the response in terms of these markers at a compensated state after an acute saline load
Detailed Description:
All consecutive patients aged 18 years with a diagnosis of acute heart failure or exacerbation in chronic heart failure due to heart failure with reduced ejection fraction HFrEF admitted to the ward of Internal Medicine were enrolled from March 2017 to June 2019 Enrolled subjects were treated with treatment with hypertonic saline solutions furosemide ev and control subjects with congestive heart failure randomized to treatment with intravenous furosemide only Chronic kidney disease patients undergoing dialysis replacement acute coronary syndrome myocarditis pneumonia myopathies neoplasms have been excluded
Patients underwent at T0 at 24 hours from admission T1 after 6-8 days after treatment with high dose furosemide HSS T2 after a saline load venepuncture to obtain venous blood samples for the determination of serum concentrations of N terminal pro B-type natriuretic peptide High-sensitive cardiac troponin T Galectin 3 IL-6
Patients underwent at T0 at 24 hours from admission T1 after 6-8 days after treatment with high dose furosemide HSS T2 after a saline load venepuncture to obtain venous blood samples for the determination of serum concentrations of N terminal pro B-type natriuretic peptide High-sensitive cardiac troponin T Galectin 3 IL-6
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None